In non-small cell lung carcinoma (NSCLC), 70% of patients with Epidermal Growth Factor Receptor (EGFR) activating mutations will have a favorable initial response to EGFR inhibitors gefitinib or erlotinib [35]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.